Oruka Therapeutics enters the final week of September with short sellers rebuilding positions at their fastest pace in months — yet the lending market remains wide open and options traders are leaning decidedly bullish, creating an unusual split in how pessimists and optimists are expressing their views.
Short interest is the clearest place to start. Bears have added meaningfully in recent weeks. SI hit 17.9% of the free float as of September 22 — up roughly 10% on the week and 15% over the past month. That is a sustained, deliberate rebuild, not a blip. The ORTEX short score has moved in lockstep, climbing from 63.7 on September 9 to 70.4 by September 22, its highest reading of the recent window. Whatever is drawing shorts back to the name, it has been a consistent trend, not a reactive spike.
The contradiction is in the lending market. Despite the scale of short positioning, availability has tightened sharply this week but remains comfortable in absolute terms — dropping from roughly 366% to 224% over five sessions. That is still well above the 52-week low of 44%, and borrowing costs fell nearly 31% on the week to just 0.39%. The message from the lending market is that shorts have found it easy and cheap to get into position. There is no squeeze pressure embedded in current borrow conditions; the cost-to-borrow has been drifting lower even as the short count grows. Options traders are pointing in the opposite direction entirely. The put/call ratio is running below its 20-day average — 0.40 against a mean of 0.45 — and is near its 52-week low of 0.32. That is call-heavy positioning, suggesting equity investors are buying upside rather than hedging. The divergence between a rebuilding short base and call-skewed options activity is the defining tension in ORKA right now.
The Street is broadly constructive on the name, though no firm has moved a target recently enough to change the narrative. The analyst consensus clusters around Buy, with price targets ranging from $120 to $200 against a current price of $94.55 — a mean target of $153.75, implying roughly 63% upside from here. The bull case rests on upcoming data readouts for lead candidate ORKA-001 in psoriasis, the recently initiated Phase 2 trial for ORKA-002 in hidradenitis suppurativa (data expected in Q1 2027), and the newly disclosed ORKA-004 programme in TL1A. The bear case is straightforward: no approved products, persistent net losses, and a crowded Th17 pathway. The EPS surprise factor score ranks in the 80th percentile — the company has a habit of beating expectations — but the short score rank sits in just the 18th percentile, which reflects the elevated short interest rather than an imminent squeeze setup. The price-to-book multiple has eased about 6% over the past 30 days as the stock pulled back 12% from its month-ago level, though it has clawed back 2.5% this week to close at $94.55.
Institutional ownership tells a story of fresh conviction. FMR added over 1.6 million shares to reach 13.7% of the company. BlackRock added 1.5 million shares. Capital Research built an entirely new position of 3.4 million shares. T. Rowe Price added 1.2 million shares. That is four significant buyers arriving or expanding in the most recent reported period — a pattern that at least partly explains why the stock has held up despite the short rebuild. The question heading into November 10 earnings is whether those institutional buyers are anchored to the upcoming data catalysts or the longer pipeline story, and whether the short sellers rebuilding at 17.9% of float are positioned for a data miss or simply fading a 200%-plus year-to-date run that has left valuation stretched relative to the loss-making fundamentals.
KYMR and CGON — two moderately correlated peers — both gained around 7-8% on the week, roughly in line with ORKA's 2.5% move, suggesting no unusual sector tailwind or headwind driving the stock independently this week.
What to watch next: the trajectory of the short score through October, whether availability continues to tighten toward the 52-week low at 44%, and any interim clinical communication ahead of the November 10 earnings event.
See the live data behind this article on ORTEX.
Open ORKA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
